Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Argenx Enters Japan With Smooth Approval – How Was It Possible?

Strategy Behind Unusual Move

Executive Summary

Belgian bioventure Argenx has made an unusually smooth commercial entry to Japan with Vyvgart almost as fast as the launch of the myasthenia gravis drug in the US. Its founder admits it was a “bold move” for a European pharma company and revealed how the unexpected entrance was made possible.

You may also be interested in...



BioMarin’s Roctavian & Argenx’s Efgartigimod Among Eight Hopefuls Awaiting EU Verdict

Will BioMarin be second time lucky with its hemophilia gene therapy Roctavian in the EU? The European Medicines Agency could soon decide whether the product should be approved.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.

UK Early Access Granted For Argenx’s Generalized Myasthenia Gravis Treatment

Patients in the UK with generalized myasthenia gravis are being allowed to receive argenx’s yet-to-be approved drug efgartigimod.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel